Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant Phase 2a for Hot Flashes
NCT05419908Phase 2Completed
- Sponsor
- Ogeda
- Start
- Sep 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hot flashes comparing Fezolinetant with Placebo (2 arms). Primary endpoint: Weekly General Hot Flash Score at 12 weeks. Started Sep 2015; status: completed.
02
Drugs
fezolinetant
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT05419908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419908.